| Literature DB >> 20603707 |
S Arends1, A Spoorenberg, G A W Bruyn, P M Houtman, M K Leijsma, C G M Kallenberg, E Brouwer, E van der Veer.
Abstract
SUMMARY: Osteoporosis is a well recognized complication of ankylosing spondylitis (AS). This study indicates that increased bone turnover, inflammation, and low vitamin D levels are important in the pathophysiology of AS-related osteoporosis, and that bone turnover markers (BTM) are valuable markers to detect bone loss in AS.Entities:
Mesh:
Substances:
Year: 2010 PMID: 20603707 PMCID: PMC3073049 DOI: 10.1007/s00198-010-1338-7
Source DB: PubMed Journal: Osteoporos Int ISSN: 0937-941X Impact factor: 4.507
Characteristics of the AS study population (n = 128)
| Age (years) | 41.0 ± 11.1 | ||
| Gender (male) ( | 93 (73) | ||
| Disease duration (years) | 14 (1–53) | ||
| HLA-B27+ ( | 102 (84) | ||
| NSAID use ( | 100 (78) | ||
| DMARD use ( | 18 (14) | ||
| BASDAI (range 0–10) | 6.0 ± 1.6 | BASDAI ≥ 4 ( | 116 (89) |
| ESR (mm/h) | 20 (2–90) | Increased ESR ( | 95 (74) |
| CRP (mg/L) | 14 (2–92) | Increased CRP ( | 99 (77) |
| ASDAS | 3.7 ± 0.8 | ||
| BASFI (range 0–10) | 5.6 ± 2.0 | ||
| LS BMD T-score | −0.68 ± 1.41 | Osteopenia LS ( | 41 (39) |
| Osteoporosis LS ( | 9 (9) | ||
| Hip BMD T-score | −0.52 ± 1.06 | Osteopenia hip ( | 42 (39) |
| Osteoporosis hip ( | 2 (2) | ||
| VF ( | 41 (39) | VF grade 1 ( | 27 (25) |
| VF grade 2 ( | 14 (13) | ||
| VF grade 3 ( | 0 (0) | ||
| PINP (μg/L) | 42.7 (16.0–101.5) | ||
| PINP Z-score | 0.14 (−1.74–3.55) | ||
| sCTX (pg/ml) | 200.3 (13.4–780.9) | ||
| sCTX Z-score | −0.36 (−2.58–5.90) | ||
| OC (μg/L) | 12.7 (0.1–24.9) | ||
| OC Z-score | −0.28 (−2.86–2.52) | ||
| 25OHvitD (nmol/L) | 61.4 (13.8–186) | Poor vitamin D status ( | 30 (26) |
Values are mean ± SD or median (range) unless otherwise indicated
AS Ankylosing Spondylitis, HLA-B27+ human leukocyte antigen B27 positive, NSAID non-steroidal anti-inflammatory drug, DMARD disease-modifying antirheumatic drug, BASDAI Bath Ankylosing Spondylitis Disease Activity Index, ESR erythrocyte sedimentation rate, CRP C-reactive protein, ASDAS ASAS-endorsed disease activity score, BASFI Bath Ankylosing Spondylitis Functional Index, LS lumbar spine, BMD bone mineral density, VF vertebral fracture, PINP procollagen type 1 N-terminal peptide, sCTX serum C-telopeptides of type I collagen, OC osteocalcin, 25OHvitD 25-hydroxyvitamin D
Correlations between clinical and biochemical assessments in AS patients with active disease (n = 128)
| Age | Disease duration | BASDAI | ESR | CRP | ASDAS | BASFI | PINP Z | sCTX Z | OC Z | LS BMD T | Hip BMD T | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Disease duration (years) | 0.600a | – | ||||||||||
| BASDAI (range 0–10) | NS | NS | – | |||||||||
| ESR (mm/h) | NS | NS | NS | – | ||||||||
| CRP (mg/L) | NS | NS | NS | 0.693a | – | |||||||
| ASDAS | NS | 0.187a | 0.651a | 0.374a | 0.668a | – | ||||||
| BASFI (range 0–10) | NS | 0.203a | 0.561a | NS | NS | 0.472a | – | |||||
| PINP Z-score | 0.362a | 0.266a | NS | NS | NS | NS | NS | – | ||||
| sCTX Z-score | NS | 0.200a | NS | NS | NS | NS | NS | 0.443a | – | |||
| OC Z-score | NS | NS | NS | NS | NS | NS | NS | 0.578a | 0.601a | – | ||
| LS BMD T-score | NS | NS | 0.205a | NS | NS | NS | NS | NS | NS | NS | – | |
| Hip BMD T-score | NS | NS | NS | NS | NS | NS | NS | NS | −0.380a | −0.272a | 0.626a | – |
| 25OHvitD (nmol/L) | NS | NS | NS | NS | NS | NS | NS | NS | NS | NS | NS | NS |
aStatistically significant correlation (p < 0.05)
See Table 1 for definitions
Fig. 1The difference between lumbar spine and hip BMD T-score positively correlated with disease duration (ρ = 0.340, p < 0.05). Patients with long disease duration never had a lumbar spine BMD T-score that was much lower than their hip BMD T-score, which indicates that osteoproliferation in the lumbar spine has resulted in an overestimation of the lumbar spine BMD T-score in patients with advanced AS
Results of univariate and multivariate logistic regression analysis for low BMD
| Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|
| OR (95% CI) |
| OR (95% CI) |
| |
| Age (years)a | 1.017 (0.981–1.055) | 0.353 | 1.066 (1.008–1.129) | 0.026 |
| Genderb | 4.368 (1.791–10.652) | 0.001 | –e | |
| Disease duration (years)a | 1.012 (0.974–1.052) | 0.539 | –e | |
| BASDAI (range 0–10)c | 0.728 (0.554–0.957) | 0.023 | 0.648 (0.455–0.923) | 0.016 |
| ESR (mm/h)c | 1.012 (0.980–1.034) | 0.287 | 1.025 (0.994–1.057) | 0.112 |
| CRP (mg/L)c | 1.018 (0.994–1.042) | 0.143 | –e | |
| ASDASc | 0.769 (0.461–1.283) | 0.315 | –f | |
| BASFI (range 0–10)c | 0.959 (0.790–1.165) | 0.674 | –f | |
| PINP Z-scorec | 1.602 (1.043–2.461) | 0.031 | –e | |
| sCTX Z-scorec | 1.878 (1.262–2.794) | 0.002 | 2.563 (1.370–4.794) | 0.003 |
| OC Z-scorec | 1.766 (1.135–2.749) | 0.012 | –e | |
| 25OHvitD (nmol/L)c | 0.998 (0.983–1.013) | 0.787 | –e | |
| VFd | 0.902 (0.385–2.109) | 0.811 | –f | |
See Table 1 for definitions
OR refers to the risk of low BMD (lumbar spine or hip BMD T-score ≤ −1)
aPer year
bIf gender is male (versus female)
cPer 1 grade or 1 point
dIf vertebral fracture is present (versus absent)
eThe variable was not selected during multivariate regression analysis
fThe variable was not tested in multivariate regression analysis because of a p value > 0.3 in univariate regression analysis, no significant correlation with lumbar spine or hip BMD T-scores, and no significant difference between men and women
Results of univariate and multivariate linear regression analysis for sCTX Z-score
| Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|
| B (95% CI) |
| B (95% CI) |
| |
| Age (years)a | 0.018 (−0.004–0.041) | 0.112 | –d | |
| Genderb | −0.680 (−1.211–−0.148) | 0.013 | –d | |
| Disease duration (years)a | 0.018 (−0.005–0.041) | 0.114 | –d | |
| BASDAI (range 0-10)c | −0.060 (−0.213–0.092) | 0.436 | –e | |
| ESR(mm/h)c | 0.011 (−0.002–0.025) | 0.102 | 0.012 (0.000−0.025) | 0.069 |
| CRP(mg/L)c | 0.007 (−0.007–0.021) | 0.303 | –d | |
| ASDASc | 0.156 (−0.174–0.486) | 0.351 | –e | |
| BASFI (range 0–10)c | 0.004 (−0.124–0.132) | 0.953 | –e | |
| PINP Z-scorec | 0.581 (0.384–0.777) | 0.000 | 0.292 (0.022–0.563) | 0.035 |
| OC Z-scorec | 0.774 (0.577–0.971) | 0.000 | 0.505 (0.243–0.768) | 0.000 |
| 25OHvitD (nmol/L)c | −0.011 (−0.020–−0.002) | 0.020 | −0.009 (–0.018–0.000) | 0.041 |
See Table 1 for definitions
B refers to the influence on sCTX Z-score
aPer year
bIf gender is male (versus female)
cPer 1 grade or 1 point
dThe variable was not selected during multivariate regression analysis
eThe variable was not tested in multivariate regression analysis because of a p value>0.3 in univariate regression analysis, no significant correlation with sCTX Z-score, and no significant difference between men and women
Results of univariate and multivariate linear regression analysis for OC Z-score
| Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|
| B (95% CI) |
| B (95% CI) |
| |
| Age (years)a | 0.008 (−0.011–0.027) | 0.409 | −0.018 (−0.034–−0.001) | 0.036 |
| Genderb | −0.687 (−1.129–−0.244) | 0.003 | −0.607 (−0.999–−0.214) | 0.003 |
| Disease duration (years)a | 0.007 (−0.012–0.026) | 0.460 | –e | |
| BASDAI (range 0–10)c | −0.029 (−0.155–0.098) | 0.655 | –e | |
| ESR (mm/h)c | 0.006 (−0.005–0.018) | 0.284 | –d | |
| CRP (mg/L)c | 0.009 (−0.003–0.022) | 0.130 | –d | |
| ASDASc | 0.052 (−0.222–0.326) | 0.708 | –e | |
| BASFI (range 0–10)c | 0.035 (−0.071–0.141) | 0.651 | –e | |
| PINP Z-scorec | 0.605 (0.453–0.756) | 0.000 | 0.464 (0.282–0.646) | 0.000 |
| sCTX Z-scorec | 0.464 (0.346–0.582) | 0.000 | 0.243 (0.110–0.377) | 0.000 |
| 25OHvitD (nmol/L)c | −0.007 (−0.016–0.001) | 0.076 | ||
See Table 1 for definitions
B refers to the influence on OC Z-score
aPer year
bIf gender is male (versus female)
cPer 1 grade or 1 point
dThe variable was not selected during multivariate regression analysis
eThe variable was not tested in multivariate regression analysis because of a p value>0.3 in univariate regression analysis, no significant correlation with OC Z-score, and no significant difference between men and women